ClinicalTrials.gg
Not yet recruitingNCT07389941SPICE-AFUpdated Feb 11, 2026

Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation

A Phase 4 interventional study of Semaglutide (SEMA) in Atrial Fibrillation (AF), sponsored by University of Luebeck. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by University of Luebeck · Phase 4, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Atrial Fibrillation by University of Luebeck — 6 open to participants now, 6 under way, none of them phase 3. Atrial Fibrillation · University of Luebeck.

Started
2026
with 2 others
Phase 4
Only one
of the 12
Registered
10th of 12
by date

Among the 12 studies in Atrial Fibrillation by University of Luebeck, this one is one of 3 that started in 2026, is the only one in phase 4, and was the 10th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

6 of the 12 studies in Atrial Fibrillation by University of Luebeck are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Atrial Fibrillation by University of Luebeck, or all of them as a file.
02

Study summary

To evaluate whether pre-treatment with semaglutide is superior to standard care in improving freedom from atrial fibrillation (AF) at 12 months following catheter ablation in patients with obesity and symptomatic AF undergoing first-time ablation.

03

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80 years
  • Symptomatic paroxysmal or persistent AF eligible for first-time catheter ablation
  • ≥30 kg/m or body mass index ≥28 kg/m plus ≥1 weight-related comorbidity
  • No prior treatment with glucacon-like peptide-1 receptor agonists

Exclusion criteria

Exclusion criteria:

  • Current use of glucacon-like peptide-1 receptor agonists or dipeptidyl peptidase 4 inhibitors or use within the last 90 days prior to screening
  • Current antiobesity medication use or use within the last 90 days prior to screening
  • A self-reported change in body weight of >5 kg within 30 days before screening
  • History of bariatric surgery
  • History of diabetes mellitus
  • Hospitalization for unstable angina, or \<30 days prior to screening
  • Pulmonary embolism \<90 days before screening
  • Myocardial infarction, or stroke \<90 days prior to screening
  • Uncontrolled thyroid disease: thyroid-stimulating hormone >10.0 mIU/L or \<0.4 mIU/L at screening
  • Active
  • Acute pancreatitis \<180 days before screening
  • History or presence of chronic pancreatitis
  • Chronic kidney disease with \<30 mL/min
  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
  • Chronic inflammatory conditions requiring and/or on
  • Pregnancy, breast-feeding or planning pregnancy
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Catheter ablation for atrial fibrillation plus semaglutide

    Catheter ablation for atrial fibrillation plus semaglutide (up to 2.4 mg weekly)

    Drug: Semaglutide (SEMA)

  • No intervention
    Catheter ablation for atrial fibrillation and no glucacon-like peptide-1 receptor therapy

    Catheter ablation for atrial fibrillation and no glucacon-like peptide-1 receptor therapy (standard therapy)

Interventions

06

What researchers measure

Primary outcomes

  1. Freedom from atrial arrhythmia (AF/atrial flutter/atrial tachycardia >30 sec) at 12 months post-ablation (8-week-blanking period)

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Apr 2029, 30 months later.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 30 months is below that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 5, 2026
StartEst.
Oct 2026
Primary completionEst.
Apr 2029
CompletionEst.
Apr 2029
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07389941
Lead sponsor
University of Luebeck
Responsible party
Roland Richard Tilz, MD (Director, Department of Rhythmology, University of Luebeck) — Principal investigator
First posted
Feb 5, 2026
Start date
Oct 2026 (estimated)
Primary completion
Apr 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
Feb 11, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion